Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies
Copyright © 2023 Elsevier B.V. All rights reserved..
Oncolytic viruses (OVs) have emerged as a clinical therapeutic modality potentially effective for cancers that evade conventional therapies, including central nervous system malignancies. Rationally designed combinatorial strategies can augment the efficacy of OVs by boosting tumor-selective cytotoxicity and modulating the tumor microenvironment (TME). Photodynamic therapy (PDT) of cancer not only mediates direct neoplastic cell death but also primes the TME to sensitize the tumor to secondary therapies, allowing for the combination of two potentially synergistic therapies with broader targets. Here, we created G47Δ-KR, clinical oncolytic herpes simplex virus G47Δ that expresses photosensitizer protein KillerRed (KR). Optical properties and cytotoxic effects of G47Δ-KR infection followed by amber LED illumination (peak wavelength: 585-595 nm) were examined in human glioblastoma (GBM) and malignant meningioma (MM) models in vitro. G47Δ-KR infection of tumor cells mediated KR expression that was activated by LED and produced reactive oxygen species, leading to cell death that was more robust than G47Δ-KR without light. In vivo, we tested photodynamic-oncolytic virus (PD-OV) therapy employing intratumoral injection of G47Δ-KR followed by laser light tumor irradiation (wavelength: 585 nm) in GBM and MM xenografts. PD-OV therapy was feasible in these models and resulted in potent anti-tumor effects that were superior to G47Δ-KR alone (without laser light) or laser light alone. RNA sequencing analysis of post-treatment tumor samples revealed PD-OV therapy-induced increases in TME infiltration of variable immune cell types. This study thus demonstrated the proof-of-concept that G47Δ-KR enables PD-OV therapy for neuro-oncological malignancies and warrants further research to advance potential clinical translation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:572 |
|---|---|
| Enthalten in: |
Cancer letters - 572(2023) vom: 28. Sept., Seite 216363 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shimizu, Kazuhide [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Glioblastoma |
|---|
| Anmerkungen: |
Date Completed 06.09.2023 Date Revised 03.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2023.216363 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361181078 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361181078 | ||
| 003 | DE-627 | ||
| 005 | 20231226084605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2023.216363 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM361181078 | ||
| 035 | |a (NLM)37619813 | ||
| 035 | |a (PII)S0304-3835(23)00314-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shimizu, Kazuhide |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2023 | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Oncolytic viruses (OVs) have emerged as a clinical therapeutic modality potentially effective for cancers that evade conventional therapies, including central nervous system malignancies. Rationally designed combinatorial strategies can augment the efficacy of OVs by boosting tumor-selective cytotoxicity and modulating the tumor microenvironment (TME). Photodynamic therapy (PDT) of cancer not only mediates direct neoplastic cell death but also primes the TME to sensitize the tumor to secondary therapies, allowing for the combination of two potentially synergistic therapies with broader targets. Here, we created G47Δ-KR, clinical oncolytic herpes simplex virus G47Δ that expresses photosensitizer protein KillerRed (KR). Optical properties and cytotoxic effects of G47Δ-KR infection followed by amber LED illumination (peak wavelength: 585-595 nm) were examined in human glioblastoma (GBM) and malignant meningioma (MM) models in vitro. G47Δ-KR infection of tumor cells mediated KR expression that was activated by LED and produced reactive oxygen species, leading to cell death that was more robust than G47Δ-KR without light. In vivo, we tested photodynamic-oncolytic virus (PD-OV) therapy employing intratumoral injection of G47Δ-KR followed by laser light tumor irradiation (wavelength: 585 nm) in GBM and MM xenografts. PD-OV therapy was feasible in these models and resulted in potent anti-tumor effects that were superior to G47Δ-KR alone (without laser light) or laser light alone. RNA sequencing analysis of post-treatment tumor samples revealed PD-OV therapy-induced increases in TME infiltration of variable immune cell types. This study thus demonstrated the proof-of-concept that G47Δ-KR enables PD-OV therapy for neuro-oncological malignancies and warrants further research to advance potential clinical translation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Glioblastoma | |
| 650 | 4 | |a KillerRed | |
| 650 | 4 | |a Malignant meningioma | |
| 650 | 4 | |a Oncolytic herpes simplex virus | |
| 650 | 4 | |a Photodynamic therapy | |
| 700 | 1 | |a Kahramanian, Andranik |e verfasserin |4 aut | |
| 700 | 1 | |a Jabbar, Muzammil Arif Din Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Turna Demir, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Gokyer, Dilan |e verfasserin |4 aut | |
| 700 | 1 | |a Uthamacumaran, Abicumaran |e verfasserin |4 aut | |
| 700 | 1 | |a Rajan, Anant |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Mohammad Ahsan |e verfasserin |4 aut | |
| 700 | 1 | |a Gorham, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Wakimoto, Hiroko |e verfasserin |4 aut | |
| 700 | 1 | |a Martuza, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Rabkin, Samuel D |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Tayyaba |e verfasserin |4 aut | |
| 700 | 1 | |a Wakimoto, Hiroaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 572(2023) vom: 28. Sept., Seite 216363 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:572 |g year:2023 |g day:28 |g month:09 |g pages:216363 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2023.216363 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 572 |j 2023 |b 28 |c 09 |h 216363 | ||